



06/11/04

FW

Attorney Docket No. 29635-714.201

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of:	Group Art Unit: Not yet assigned
Applicant: Widder <i>et al.</i>	Examiner: Not yet assigned
Serial No.: 10/783,871	<u>Certificate of Mailing Under C.F.R. §1.8</u>
Filed: February 20, 2004	I hereby certify that this correspondence and all marked attachments are being deposited by Express Mail, Express Mailing Label Nos.: EV 334638784 US, EV334638753 US, and EV 334638775 US on June 9, 2004 addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Title: <i>A Novel Formulation, Omeprazole Antacid Complex-Immediate Release, For Rapid and Sustained Suppression of Gastric Acid</i>	By: <u><i>Amy E. Bathke</i></u> Amy Bathke

SNH828E94EEVA3

SN528E94EEVA3
SN528E94EEVA3

INFORMATION DISCLOSURE STATEMENT

MAIL STOP NON-FEE AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement (IDS) is being filed within the period specified at 37 C.F.R. § 1.97(b). Specifically, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits. In the event an Office Action has been mailed, then this IDS is being mailed under 37 C.F.R. § 1.97(c), and the USPTO is authorized to charge the fee required to Applicant's deposit account as indicated below.

Copies of the cited documents are enclosed.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form

to Applicant.

The IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 C.F.R. § 97(f), to enable Applicant to fully comply.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 C.F.R. § 1.17(p) in the event that the period specified at 37 C.F.R. § 1.97(b) has lapsed, please charge all required fees to Deposit Account No. 23-2415.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI
Professional Corporation

Date: 9-Jun-04




Aubrey A. Haddach

Registration No. 48,374

3611 Valley Centre Drive, Suite 525

San Diego, CA 92130-3317

(858) 350-2319



06/11/04

17W

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 47

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	29635-714.201

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US- 2002/0192299 A1	12-19-2002	Taneja et al.	
	2	US- 2003/0144306 A1	07-31-2003	Phillips	
	3	US- 2003/0215527 A1	11-20-2003	Phillips	
	4	US- 2004/0048896 A1	03-11-2004	Phillips	
	5	US- 2004/0058018 A1	03-25-2004	Phillips	
	6	US- 4,045,564	08-30-1977	Berntsson et al.	
	7	US- 4,182,766	01-08-1980	Krasso et al.	
	8	US- 4,255,431	03-10-1981	Junggren et al.	
	9	US- 4,337,257	06-29-1982	Junggren et al.	
	10	US- 4,359,465	11-16-1982	Ruwart	
	11	US- 4,414,216	11-08-1983	Kawakita et al.	
	12	US- 4,472,409	09-18-1984	Senn-Bilfinger	
	13	US- 4,508,905	04-02-1985	Junggren et al.	
	14	US- 4,544,750	10-01-1985	Brandstrom et al.	
	15	US- 4,620,008	10-28-1986	Brandstrom et al.	
	16	US- 4,636,499	01-13-1987	Brandstrom et al.	
	17	US- 4,725,691	02-16-1988	Brandstrom et al.	
	18	US- 4,738,974	04-19-1988	Brandstrom	
	19	US- 4,786,505	11-22-1988	Lovgren et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	20	CA 1,234,118	03-15-1988	Aktiebolaget Hassle		
	21	DE 19,752,843 C2	01-09-2003	Rango, D.		
	22	EP 0,005,129 A1	10-31-1979	Aktiebolaget Hassle		
	23	EP 0,005,129 B1	04-29-1981	Aktiebolaget Hassle		
	24	EP 0,308,515 A1	03-29-1989	Yoshitomi Pharmaceutical		
	25	EP 0,308,515 B1	01-26-1994	Yoshitomi Pharmaceutical		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2of 47**Complete if Known**

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	29635-714.201

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	26	US- 4,853,230	08-01-1989	Lovgren at al.	
	27	US- 4,965,351	10-23-1990	Caruso et al.	
	28	US- 4,985,548	01-15-1991	Caruso et al.	
	29	US- 5,008,278	04-16-1991	Brandstrom et al.	
	30	US- 5,013,743	05-07-1991	Iwahi et al.	
	31	US- 5,019,584	05-28-1991	Brandstrom et al.	
	32	US- 5,025,024	06-18-1991	Brandstrom et al.	
	33	US- 5,039,806	08-13-1991	Brandstram et al.	
	34	US- 5,045,321	09-03-1991	Makino et al.	
	35	US- 5,075,323	12-24-1991	Fain et al.	
	36	US- 5,093,132 A	03-03-1992	Makino et al.	
	37	US- 5,093,342 A	03-03-1992	Tomoi et al.	
	38	US- 5,106,862 A	04-21-1992	Briving et al.	
	39	US- 5,124,158 A	06-23-1992	Ruwart et al.	
	40	US- 5,215,974 A	06-01-1993	Alminger et al.	
	41	US- 5,219,870 A	06-15-1993	Kim	
	42	US- 5,232,706 A	08-03-1993	Palomo Coll	
	43	US- 5,244,670 A	09-14-1993	Upson et al.	
	44	US- 5,288,506 A	02-22-1994	Spickett et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	45	EP 0,040,639 A1	12-02-1981	Yoshitomi Pharm		
	46	EP 0,040,639 B1	05-30-1984	Yoshitomi Pharm		
	47	EP 0,237,200 B1	07-01-1992	Takeda Chemical		
	48	EP 0,244,380 A2	11-04-1987	Aktiebolaget Hassle		
	49	EP 0,244,380 B1	01-07-1993	Aktiebolaget Hassle		
	50	EP 0,247,983 A2	12-02-1987	Aktiebolaget Hassle		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

Complete if Known

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	51	US- 5,374,730 A	12-20-1994	Slemon et al.	
	52	US- 5,385,739 A	01-31-1995	Debregeas et al.	
	53	US- 5,386,032 A	01-31-1995	Brandstrom	
	54	US- 5,391,752 A	02-21-1995	Hoermer et al.	
	55	US- 5,395,323 A	03-07-1995	Berglund	
	56	US- 5,399,700 A	03-21-1995	Min et al.	
	57	US- 5,417,980 A	05-23-1995	Goldman et al.	
	58	US- 5,430,042 A	07-04-1995	Lindberg et al.	
	59	US- 5,447,918 A	09-05-1995	McCullough	
	60	US- 5,447,923 A	09-05-1995	Catrenich et al.	
	61	US- 5,470,983 A	11-28-1995	Slemon et al.	
	62	US- 5,504,082 A	04-02-1996	Kawakita et al.	
	63	US- 5,589,491 A	12-31-1996	Nakanishi et al.	
	64	US- 5,599,794 A	02-04-1997	Eek et al.	
	65	US- 5,629,305 A	05-13-1997	Eek et al.	
	66	US- 5,633,244 A	05-27-1997	Eek et al.	
	67	US- 5,639,478 A	06-17-1997	Makino et al.	
	68	US- 5,690,960 A	11-25-1997	Bengtsson et al.	
	69	US- 5,693,818 A	12-02-1997	Von Unge	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
	70	EP 0,247,983 B1	01-07-1993	Aktiebolaget Hassle	
	71	EP 0,248,634 A2	12-09-1987	Nippon Chemiphar	
	72	EP 0,248,634 B1	07-21-1993	Nippon Chemiphar	
	73	EP 0,308,515 B1	01-26-1994	Aktiebolaget Hassle	
	74	EP 0,315,964 A1	05-17-1989	Fujisawa Pharmaceutical	
	75	EP 0,315,964 B1	01-07-1993	Laboratoires Pharmascience	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4

of

Complete if Known

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	76	US- 5,714,504 B1	02-03-1998	Lindberg et al.	
	77	US- 5,714,505 B1	02-03-1998	Hasselkus	
	78	US- 5,731,002 B1	03-24-1998	Olovson et al.	
	79	US- 5,753,265 B1	05-19-1998	Bergstrand et al.	
	80	US- 5,766,622 B1	06-19-1998	Nelson	
	81	US- 5,776,765 B1	07-07-1998	Graham et al.	
	82	US- 5,798,120 B1	08-25-1998	Tomohisa et al.	
	83	US- 5,814,338 B1	09-29-1998	Veronesi	
	84	US- 5,817,338 B1	10-06-1998	Bergstrand et al.	
	85	US- 5,840,737 B1	11-24-1998	Phillips	
	86	US- 5,876,759 B1	03-02-1999	Gowan, Jr.	
	87	US- 5,877,192 B1	03-02-1999	Lindberg et al.	
	88	US- 5,879,708 B1	03-09-1999	Makino et al.	
	89	US- 5,883,102 B1	03-16-1999	Hamley et al.	
	90	US- 5,885,594 B1	03-23-1999	Nilsen et al.	
	91	US- 5,900,424 B1	05-04-1999	Kallstrom et al.	
	92	US- 5,929,244 B1	07-27-1999	Von Unge	
	93	US- 5,939,091 B1	08-17-1999	Eoga et al.	
	94	US- 5,948,789 B1	09-07-1999	Larsson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	95	EP 0,338,861 B1	01-20-1993	Walton S.A.		
	96	EP 0,394,471 A1	10-31-1990	Yoshitomi-machi Chikujo-gun		
	97	EP 0,414,847 B1	09-08-1993	Aktiebolaget Hassle		
	98	EP 0,436,620 B1	08-10-1994	Morein, Bror		
	99	EP 0,452,697 A1	10-23-1991	Fujisawa Pharmaceutical		
	100	EP 0,452,697 B1	12-06-1995	Fujisawa Pharmaceutical		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5

of

Complete if Known

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	101	US- 5,955,107 A	09-21-1999	Augello et al.	
	102	US- 5,958,955 A	09-28-1999	Gustavsson et al.	
	103	US- 5,962,022 A	10-05-1999	Bolt et al.	
	104	US- 5,965,162 A	10-12-1999	Fuisz et al.	
	105	US- 5,972,389 A	10-26-1999	Shell et al.	
	106	US- 5,979,515 A	11-09-1999	Olsson	
	107	US- 6,013,281 A	01-11-2000	Lundberg et al.	
	108	US- 6,017,560 A	01-25-2000	Makino et al.	
	109	US- 6,090,827 A	07-18-2000	Erickson et al.	
	110	US- 6,123,962 A	09-26-2000	Makino et al.	
	111	US- 6,124,464 A	09-26-2000	Hogberg et al.	
	112	US- 6,132,770 A	10-17-2000	Lundberg	
	113	US- 6,132,771 A	10-17-2000	Depui et al.	
	114	US- 6,136,344 A	10-24-2000	Depui et al.	
	115	US- 6,143,771 A	11-07-2000	Lindberg et al.	
	116	US- 6,147,103 A	11-14-2000	Anousis et al.	
	117	US- 6,150,380 A	11-21-2000	Lovqvist et al.	
	118	US- 6,162,816 A	12-19-2000	Bohlin et al.	
	119	US- 6,166,213 A	12-26-2000	Anousis et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	120	EP 0,465,254 A1	01-08-1992	Yoshitomi Pharm		
	121	EP 0,496,437 A2	07-29-1992	Aktiebolaget Hassle		
	122	EP 0,496,437 A3	07-29-1996	Aktiebolaget Hassle		
	123	EP 0,496,437 B1	07-29-1992	Aktiebolaget Hassle		
	124	EP 0,502,556 A1	09-09-1992	Aktiebolaget Hassle		
	125	EP 0,502,556 B1	06-26-1992	Aktiebolaget Hassle		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6

of

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	134	EP 0,565,210 A2	10-13-1993	Aktiebolaget Hassle		
	135	EP 0,565,210 A3	06-07-1995	Aktiebolaget Hassle		
	136	EP 0,565,210 B1	11-17-1999	Astra Aktiebolag		
	137	EP 0,567,201 A2	10-27-1993	Aktiebolaget Hassle		
	138	EP 0,567,201 A3	07-06-1995	Aktiebolaget Hassle		
	139	EP 0,567,201 B1	09-15-1999	Astra Aktiebolag		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7

7

of 47

47

Complete if Known

Application Number	10/783.871
--------------------	------------

10783.871

Filing Date	20-Feb-04
-------------	-----------

20-Feb-04

First Named Inventor	Widder, et al.
----------------------	----------------

Widder, et al.

Art Unit

Examiner Name

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	7 ^d
		Country Code ² Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY			
	140	EP 0,567,643 A1	11-03-1993	Yoshitomi Pharm		
	141	EP 0,587,659 B1	05-07-1997	British Technology Grp.		
	142	EP 0,636,364 B1	09-20-2000	McNeil-PPC, Inc.		
	143	EP 0,652,751 B1	10-23-1996	Astra Aktiebolag		
	144	EP 0,654,471 A1	05-24-1995	Eisai Co., Ltd.		
	145	EP 0,654,471 B1	07-08-1998	Eisai Co., Ltd.		

**Examiner
Signature**

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8

of 47

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date: MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	146	EP 0,696,921 B1	02-07-2001	Astrazeneca AB		
	147	EP 1,004,305 A1	05-31-2000	Eisai Co., Ltd.		
	148	ES 2,024,993 A6	03-01-1992	Centro Genesis		
	149	GB 2,189,698 A	11-04-1987	Aktiebolaget Hassle		
	150	JP 02-22225 A	01-25-1990	Eisai Co., Ltd.		
	151	JP 03-34967 A	02-14-1991	Yoshitomi Pharmaceutical		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet 10

of 47

Application Number	10/783,871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	158	JP 05-255088 A	10-05-1993	Yoshitomi Pharm		
	159	JP 05-294831 A	11-09-1993	Aktiebolaget Hassle		
	160	JP 06-092853 A	04-05-1994	Fujisawa Pharm Co		
	161	JP 06-100449 A	04-12-1994	Yoshitomi Pharm		
	162	JP 07-033659 A	02-03-1995	Yoshitomi Pharm		
	163	JP 09-087110 A	03-31-1997	Yoshitomi Pharm		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11

of 47

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	164	JP 10017470 A	01-20-1998	Yoshitomi Pharm		
	165	JP 10017471 A	01-20-1998	Yoshitomi Pharm		
	166	JP 2000-212180 A	08-02-2000	Welfide Corp		
	167	JP 2000-355540 A	12-26-2000			
	168	JP 45-039541 A	12-12-1970	Yoshitomi Pharm		
	169	JP 45-039543 A	12-12-1970	Yoshitomi Pharm		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP §01.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	12
-------	----

of 47

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY			
	170	JP 46-009580 A	03-11-1971	Yoshitomi Pharm		
	171	JP 46-009581 A	03-11-1971	Yoshitomi Pharm		
	172	JP 48-103567 A	12-25-1973	Japan Chem Ind KK		
	173	JP 49-005967 A	01-19-1974	Yoshitomi Pharm		
	174	JP 49-013172 A	02-05-1974	Yoshitomi Pharm		
	175	JP 49-020173 A	02-22-1974	Yoshitomi Pharm		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	13
-------	----

of 47

Complete if Known

Application Number	10/783 871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY			
	176	JP 49-020174 A	02-22-1974	Yoshitomi Pharm		
	177	JP 49-041198 A	04-17-1974	Yoshitomi Pharm		
	178	JP 49-093537 A	09-05-1974	Yoshitomi Pharm		
	179	JP 49-095997 A	09-11-1974	Yoshitomi Pharm		
	180	JP 50-052065 A	05-09-1975	Yoshitomi Pharm		
	181	JP 50-112373 A	09-03-1975	Yoshitomi Pharm		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	14
-------	----

of 47

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	182	JP 50-142565 A	11-17-1975	Yoshitomi Pharm		
	183	JP 51-016669 A	02-10-1976	Yoshitomi Pharm		
	184	JP 51-017268 A	02-12-1977			
	185	JP 51-131875 A	11-16-1976	Yoshitomi Pharm		
	186	JP 52-005769 A	01-17-1977	Yoshitomi Pharm		
	187	JP 52-014776 A	02-03-1977	Yoshitomi Pharm		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	29635-714.201

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	16
-------	----

of 47

Complete if Known

Application Number	10/783 871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	194	JP 61-221117 A	10-01-1986	Fujisawa Pharm		
	195	JP 62-145083 A	06-29-1987	Yoshitomi Pharm		
	196	JP 62-258316 A	11-10-1987	Haessel AB		
	197	JP 62-258320 A	11-10-1987	Haessel AB		
	198	JP 62-277322 A	12-02-1987	Takeda Chem Ind. Ltd.		
	199	JP 62-283964 A	12-09-1987	Astra AB		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	17	of	47
-------	----	----	----

Complete if Known

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	29635-714.201

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	200	KR 1996-0003605 B1	03-20-1996	Yungjin Pharm		
	201	KR 1996-0011238 B1	08-21-1996	Kolon Inc.		
	202	KR 1996-0011390 B1	08-22-1996	Kolon Inc.		
	203	RO 88351	04-30-1986	Puscos, I		
	204	WO 00/01372 A2	01-13-2000	Reckitt and Colman Products		
	205	WO 00/09092 A1	02-24-2000	Byk Gulden Lomberg Chem.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	18	of	47
-------	----	----	----

Application Number	10/783,871
Filing Date	20-Feb-04
First Named Inventor	Widder, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	29635-714.201

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	206	WO 00/10999 A2	03-02-2000	Astra Aktiebolag		
	207	WO 00/10999 A3	03-02-2000	Astra Aktiebolag		
	208	WO 00/15195 A1	03-23-2000	Nycomed Danmark		
	209	WO 00/26185 A2	05-11-2000	Curators of Uni. of Missouri		
	210	WO 00/26185 A3	05-11-2000	Curators of Uni. of Missouri		
	211	WO 00/27366 A1	05-18-2000	Astrazeneca AB		

Date Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	19
-------	----

of 47

Complete if Known

Application Number	10/783,871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	212	WO 00/28975 A2	05-25-2000	Astrazeneca AB		
	213	WO 00/28975 A3	05-25-2000	Astrazeneca AB		
	214	WO 00/30612 A1	06-02-2000	Astrazeneca AB		
	215	WO 00/35448 A1	06-22-2000	Astrazeneca AB		
	216	WO 00/44744 A1	08-03-2000	Astrazeneca AB		
	217	WO 00/45817 A1	08-10-2000	Astrazeneca UK Ltd.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 20

of 47

Application Number	10/783,871
--------------------	------------

10/783.871

Filing Date	20-Feb-04
-------------	-----------

20-Feb-04

First Named Inventor	Widder, et al.
----------------------	----------------

Widder, et al.

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	218	WO 0050038 A1	08-31-2000	Merck & Co. Inc		
	219	WO 0069438 A1	11-23-2000	Astrazeneca AB		
	220	WO 0078293 A1	12-28-2000	Astrazeneca AB		
	221	WO 0103707 A1	01-18-2001	Smithkline Beecham Corp.		
	222	WO 0124780 A2	04-12-2001	Natco Pharma Ltd.		
	223	WO 0134573 A1	05-17-2001	Pharmacia AB		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet 21

of 47

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number	29635-714.201
------------------------	---------------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY			
	224	WO 01/51050 A1	07-19-2001	Curators Uni. Missouri		
	225	WO 03/009846 A1	02-06-2003	Curators Uni. Missouri		
	226	WO 03/017980 A1	03-06-1989	Takeda Chem Ind Ltd.		
	227	WO 03/061584 A1	07-31-2003	Curators Uni. Missouri		
	228	WO 89/00566 A1	01-26-1989	Yoshitomi Pharm		
	229	WO 92/04898 A1	04-02-1992	Byk Gulden Lomborg Chem.		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	23
-------	----

of 47

Attorney Docket Number	29635-714.201
------------------------	---------------

Complete if Known

Application Number	10/783 871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY			
	236	WO 95/07913 A1	03-23-1993	Meiji Milk Products Co. Ltd		
	237	WO 95/15962 A1	06-15-1995	Astra Aktiebolag		
	238	WO 95/23594 A1	09-08-1995	Gergely		
	239	WO 95/32957 A1	12-07-1995	Astra Aktiebolag		
	240	WO 95/32959 A1	12-07-1995	Astra Aktiebolag		
	241	WO 96/01612 A1	01-25-1996	Therapicon S.R.L.		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/783,871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number	29635-714.201
------------------------	---------------

Sheet	24	of	47
-------	----	----	----

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	242	WO 96/01622 A1	01-25-1996	Astra Aktiebolag		
	243	WO 96/01623 A1	01-25-1996	Astra Aktiebolag		
	244	WO 96/01624 A1	01-25-1996	Astra Aktiebolag		
	245	WO 96/01625 A1	01-25-1996	Astra Aktiebolag		
	246	WO 96/02236 A1	02-01-1996	Moore, T		
	247	WO 96/16959 A1	06-06-1996	Astra Aktiebolag		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet 25

of 47

Complete if Known

Application Number	10/783,871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁴	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	248	WO 96/24338 A1	08-15-1996	Astra Aktiebolag		
	249	WO 96/24375 A1	08-15-1996	Astra Aktiebolag		
	250	WO 96/38175 A1	12-05-1996	Astra Aktiebolag		
	251	WO 97/02020 A1	01-23-1997	Byk Gulden Lomberg Chem		
	252	WO 97/02021 A1	01-23-1997	Byk Gulden Lomberg Chem		
	253	WO 97/09964 A1	03-20-1997	Astra Aktiebolag		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	26
-------	----

of 47

Attorney Docket Number	29635-714.201
------------------------	---------------

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY			
	254	WO 97/25064 A1	07-17-1997	Astra Aktiebolag		
	255	WO 97/25065 A1	07-17-1997	Astra Aktiebolag		
	256	WO 97/41114 A1	11-06-1997	Astra Aktiebolag		
	257	WO 97/48380 A1	12-24-1997	Astra Aktiebolag		
	258	WO 98/00114 A2	01-08-1998	Klinge Pharma		
	259	WO 98/02368 A1	01-22-1998	Merck Patent		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 27

of

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name _____

Attorney Docket Number

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	260	WO 98/16228 A1	04-23-1998	Astra Aktiebolag		
	261	WO 98/28294 A1	07-02-1998	Astra Aktiebolag		
	262	WO 98/40054 A1	09-17-1998	Astra Aktiebolag		
	263	WO 98/50019 A1	11-12-1998	Sage Pharmaceuticals		
	264	WO 98/53803 A1	12-03-1998	Astra Aktiebolag		
	265	WO 98/54171 A1	12-03-1998	Astra Aktiebolag		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	28
-------	----

of 47

Attorney

Complete if Known

Application Number	10/783.871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number	29635-714.201
------------------------	---------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
	266	WO 99/00380 A1	01-07-1999	Astra Aktiebolag		
	267	WO 99/08500 A2	02-25-1999	Astra Aktiebolag		
	268	WO 99/25323 A1	05-27-1999	Andrx Pharmaceuticals		
	269	WO 99/25711 A1	05-27-1999	Astra Aktiebolag		
	270	WO 99/27917 A1	06-10-1999	Byk Gulden Lomberg Chem		
	271	WO 99/29299 A1	07-17-1999	Byk Gulden Lomberg Chem		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 29

of

Complete if Known

Application Number	10/783 871
--------------------	------------

Filing Date	20-Feb-04
-------------	-----------

First Named Inventor	Widder, et al.
----------------------	----------------

Art Unit

Examiner Name

Attorney Docket Number

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	272	WO 99/29320 A1	06-17-1999	Byk Gulden Lomberg Chem		
	273	WO 99/32091 A1	07-01-1999	Astra Aktiebolag		
	274	WO 99/32093 A1	07-01-1999	Astra Aktiebolag		
	275	WO 99/45004 A1	09-10-1999	Nicox S.A.		
	276	WO 99/53918 A1	10-28-1999	Eisai Co. Ltd		
	277	WO 99/55705 A1	11-04-1999	Astra Aktiebolag		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP §901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/783,871
		Filing Date	20-Feb-04
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet 30	of 47	Attorney Docket Number	29635-714.201

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	31	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	279	ADAMS, S.P., et al., "Comments of the Report of 'Association' of Omeprazole with DNA by Phillips et al.", Mutagenesis, 1992, pp 395-396, Vol. 7, No. 5, Oxford University Press	
	280	AL-ASSI, M.T., et al., "Treatment of Helicobacter Pylori Infection with Omeprazole-Amoxicillin Combination Therapy Versus Rantidine/Sodium Bicarbonate-Amoxicillin", The American Journal of Gastroenterology, 1995, pp. 1411-1414, Vol. 90, No. 9	
	281	ANDERSSON, T., et al., "Pharmacokinetics of (14C) Omeprazole in Patients with Liver Cirrhosis", Clinical Pharmacokinetics, 1993, pp71-78, Vol. 24, No. 1	
	282	ANDERSSON, T., et al., "Pharmacokinetics of Various Single Intravenous and Oral Doses of Omeprazole", European Journal of Clinical Pharmacology, 1990, pp195-197, Vol. 39, No. 2	
	283	ANDERSSON, T., et al., "Pharmacokinetics and Bioavailability of Omeprazole After Single and Repeated Oral Administration in Healthy Subjects", British Journal of Clinical Pharmacology, 1990, pp557-563, Vol. 29 No. 5	
	284	ANDERSSON, T., "Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors: Focus on Omeprazole, Lansoprazole and Pantoprazole", Clinical Pharmacokinetics, 1996, pp9-28, Vol. 31, No. 1	
	285	ANDERSSON, T., et al., "Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole", Clinical Pharmacokinetics, 2001, pp411-426, Vol. 40, No. 6	
	286	ARVIDSSON, T., et al., "Peak Distortion in the Column Liquid Chromatographic Determination of Omeprazole Dissolved in Borax Buffer", Journal of Chromatography, 1991, pp271-276, Vol. 586, Part 2	
	287	BALABAN, D. et al., "Nasogastric Omeprazole: Effects on Gastric pH in Critically Ill Patients", The American Journal of Gastroenterology, 1997, pp 79-83, Vol. 92, No. 1	
	288	BALLARD, E., et al., "Bioequivalence Between Lansoprazole Sachet for Suspension and Intact Capsule", Gastroenterology, 2001, ppA-245, Vol. 120, No. 5, Suppl. 1. Abstract #1276	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet 32	of 47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	289	ARTURO BALLESTEROS, M., et al., "Bolus or Intravenous Infusion of Ranitidine: Effects on Gastric pH and Acid Secretion", Annals of Internal Medicine, 1990, pp334-339, Vol. 112	
	290	BARIE, P.S. and HARIRI, R.J., "Therapeutic Use of Omeprazole for Refractory Stress-Induced Gastric Mucosal Hemorrhage", Critical Care Medicine, 1992, pp899-901, Vol. 20 No. 6	
	291	BEEKMAN, S.M., "Preparation and Properties of New Gastric Antacids I: Aluminium Hydroxide-Magnesium Carbonate Dried Gels", Journal of the American Pharmaceutical Association, 1960, pp 191-200, Vol. 49	
	292	BENNETT, D.R., and DICKSON, B.D. (eds), "Gastrointestinal Drugs", The American Medical Association Drug Evaluation, The American Medical Association, Chicago, 1973, pp773-827, 2nd Edition, Publishing Sciences Group, Acton, Massachusetts, U.S.A.	
	293	BLUM, A.L., "Therapeutic Approach to Ulcer Healing", The American Journal of Medicine, Aug. 1985, pp 8-14, Vol. 79, Suppl. 2C	
	294	BONE, R.C., "Let's Agree on Terminology: Definition of Sepsis", Critical Care Med., 1991, p27, Vol. 19 No. 7	
	295	BORRERO, E., et al., "Antacids vs Sucralfate in Preventing Acute Gastrointestinal Tract Bleeding in Abdominal Aortic Surgery", Archives of Surgery, 1986, pp810-812, Vol.121	
*	296	BRUNTON, L.L., "The Pharmacologic Basis of Therapeutics, 1990, New York, p 907	
	297	CANTU, T.G. and KOREK, J.S., "Central Nervous System Reactions to Histamine-2 Receptor Blockers", Annals of Internal Medicine, 1991, pp1027-1034, Vol.114	
	298	CAOS, A., et al., "Rabeprazole for the Prevention of Pathologic and Symptomatic Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease", The American Journal of Gastroenterology 2000, pp 3081-3088, Vol. 95, No. 11	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

* Missing item

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	33	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	299	CARROLL et al., "Nasogastric Administration of Omeprazole for Control of Gastric pH", 10 World Congresses of Gastroenterology, 1994, Abstract #22P, Vol 2	
	300	CEDERBERG, C. et al., "Omeprazole: Pharmacokinetics and Metabolism in Man", Scandinavian Journal of Gastroenterology, 1989, pp 33-40, Vol. 24, Supp. 166	
	301	CEDERBERG, C. et al., "Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects", Scandinavian Journal of Gastroenterology, 1993, pp 179-184. Vol. 28, No. 2	
	302	CHING, C. and Lam, S., "Antacids- Indications and Limitations", Drugs, pp 305-317, Vol. 47, No. 2	
	303	CIOFFI, W.G. et al., "Comparison of Acid Neutralizing and Non-Acid Neutralizing Stress Ulcer Prophylaxis in Thermally Injured Patients", The Journal of Trauma, 1994, pp541-547, Vol. 36 No. 4	
	304	COOK D.J., et al., "Nosocomial Pneumonia and the Role of Gastric pH: a Meta-Analysis", Chest, 1991, pp7-13, Vol. 100 No. 1	
	305	COOK, D.J. et al., "Risk Factors for Gastrointestinal Bleeding in Critically Ill Patients", New England Journal of Medicine, Feb. 1994, pp377-381, Vol. 330 No. 6	
	306	COOK D.J., et al., Stress Ulcer Prophylaxis in the Critically Ill; a Meta-Analysis", American Journal of Medicine, 1991, pp519-527, Vol. 91	
	307	CRILL, C.M. et al., "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients", Pharmacotherapy, 1999, pp 162-180, Vol 19, No. 2	
	308	CZAJA A.J. et al., "Acute Gastroduodenal Disease After Thermal Injury: an Endoscopic Evaluation of Incidence and Natural History", New England Journal of Medicine, Oct. 1974, pp925-929, Vol. 291 No. 18	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet 34 of 47	Attorney Docket Number	29635-714.201	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	309	DEAKIN, M. and TEMPLE J.G., "Therapeutic Process- Review XXXIII: Are We Making Progress In the Drug Treatment of Oesophageal Disease?", Journal of Clinical Pharmacy and Therapeutics, 1988, pp365-374, Vol. 13, No. 6	
	310	DI IORIO, B. et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion in Normal Subjects", Trace Elements and Electrolytes, 1996, pp 47-49, Vol. 13, No. 1	
	311	DiGIACINTO, J.L. et al., "Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes", Annals of Pharmacotherapy, 2000, pp 600-605, Vol. 34, No.5	
	312	DOAN, T.T. et al., "Comparative Pharmacokinetics and Pharmacodynamics of Lansoprazole Oral capsules and Suspension in Healthy Subjects", American Journal of Health-System Pharmacists, Aug. 2001, pp 1512-1519, Vol. 58, No. 16	
	313	DOBKIN E.D. et al., "Does pH Paper Accurately Reflect Gastic pH?", Critical Care Medicine, 1990, pp985-988, Vol. 18 No. 9	
	314	DRIKS M.R. et al., "Nosocomial Pneumonia in Intubated Patients Given Sucralfate As Compared with Antacids or Histamine Type 2 Blockers. The Role of Gastric Colonization", New England Journal of Medicine, 1987, pp1376-1382, Vol. 317	
	315	EISENBERG, P.G. et al., "Prospective Trial Comparing a Combination pH Probe-Nasogastric Tube with Aspirated Gastric pH in Intensive Care Unite Patients", Critical Care Medicine, 1990, pp1092-1095, Vol. 18	
	316	EKPE, A. and JACOBSEN, T., "Effect of Various Salts on the Stability of Lansoprazole, Omeprazole, and Pantoprazole as Determined by High-Performance Liquid Chromatography", Drug Development and Industrial Pharmacy, 1999, pp1057-1065, Vol. 25, No. 9	
	317	ELLIOT, R. "Nasogastric Administration of Omeprazole", The Australian Journal of Hospital Pharmacy, 1998, pp 174-176, Vol. 28, No. 3	
	318	FABIAN T.C. et al., "Pneumonia and Stress Ulceration in Severly Injured Patients. A Prospective Evaluation of the Effects of Stress Ulcer Prophylaxis", Feb. 1993, Archives of Surgery, pp185-192, Vol. 128	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet 35	of 47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	319	FELLENUS E. et al., "Substituted Benzimidazoles Inhibit Gastric Acid Secretion by Blocking (H ⁺ + K ⁺) ATPase", Nature, Mar. 1981, pp159-161, Vol. 290	
	320	FIDDIAN-GREEN R.G. et al., "Predictive Value of Intramural pH and Other Risk Factors for Massive Bleeding from Stress Ulceration", Gastroenterology, 1983, pp 613-620, Vol.85	
	321	FITTON, A. and WISEMAN, L., "Pantoprazole, A Review of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders", Drugs, Mar. 1996, pp460-482, Vol. 51, No. 3	
	322	FRYKLUND et al., "Function and Structure of Parietal Cells After H ⁺ - K ⁺ -ATPase Blockade ", American Journal of Physiology, 1988, , ppG399-407, Vol. 254, No. 3 pt 1	
	323	FUCHS, C., "Antacids: Their Function, Formulation, and Evaluation", Drug and Cosmetic Industry, Jun. 1949, Vol. 64 no. 6, pp 692-773	
	324	GAFTER, U. et al., "Thrombocytopenia Associated with Hypersensitivity to Rantidine: Possible Cross-Reactivity with Cimetidine", American journal of Gastroenterology. 1989, pp 560-562, Vol.84 No. 5	
	325	GARNER J.S. et al., "CDC Definitions for Nosocomial Infections, 1988", American Journal of Infection Control", 1988, pp128-140, Vol. 16	
	326	GARNETT, W.R., "Efficacy, Safety, and Cost Issues in Managing Patients with Gastroesophageal Reflux Diseases", American Journal of Hospital Pharmacy, 1993, pp 511-518, Vol 50 Supp. 1	
	327	GRAY et al., "Influence of Insulin Antibodies on Pharmacokinetics and Bioavailability of Recombinant Human and Highly Purified Beef Insulins in Insulin Dependant Diabetics", British Medical Journal, Jun 1985, pp 1687-1690, Vol. 290	
	328	HARDY, P. et al., "Inhibition of Gastric Secretion by Omeprazole and Efficiency of Calcium Carbonate on the Control of Hyperphosphatemia in Patients on Chronic Hemodialysis", Artificial Organs, 1998, pp 569-573, Vol. 22, No. 7	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	36	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	329	HATLEBAKK, J.G. et al., "Lansoprazole Capsules and Amoxicillin Oral Suspension in the Treatment of Peptic Ulcer Disease", Scandinavian Journal of Gastroenterology, 1995, pp 1053-1057, Vol. 30, No. 11	
	330	HEATH et al., "Intragastric pH Measurement Using a Novel Disposable Sensor", Intensive Care Med, 1988, pp 232-235, Vol.14	
	331	HIXSON, "Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease", Arch. Intern. Med., 1992, pp 171-723, Vol. 152, No.4.	
	332	HIXSON, et al., "Current Trends in the Pharmacotherapy for Peptic Ulcer Disease", Archives of Internal Medicine, 1992, pp 726-732, Vol. 152, No. 4	
	333	HOLBERT, J.M. et al., "A Study of Antacid Buffers: The Time Factor in Neutralization of Gastric Acidity", Journal of the American Pharmaceutical Association (Scientific Edition), 1947, pp 149-151, Vol. 36.	
	334	HOLT, S. and HOWDEN, C.W., "Omeprazole, Overview and Opinion", Digestive Diseases and Sciences, 1991, pp 385-393, Vol. 36, No. 4	
	335	HORN, J., "The Proton-Pump Inhibitors: Similarities and Differences", Clinical Therapeutics, 2000, pp 266-280, Vol. 22, No. 3	
	336	HOWDEN, C.W. et al., "Oral Pharmacokinetics of Omeprazole", European Journal of Clinical Pharmacology, 1984, pp 641-643, Vol. 26	
	337	HUMPHRIES, T.J. and Merritt, G.J., "Review Article: Drug Interactions with Agents Used to Treat Acid-Related Diseases", Alimentary Pharmacology & Therapeutics, 1999, pp 18-26, Vol. 13, Supp. 3	
	338	JUNGnickel, P.W., "Pantoprazole: A New Proton Pump Inhibitor", Clinical Therapeutics, 2000, pp 1268-1293, Vol. 22, No. 11	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	37	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	339	KAROL, M.D. et al., "Pharmacokinetics of Lansoprazole in Hemodialysis Patients", Journal of Clinical Pharmacology, 1995, pp 815-820, Vol. 35	
	340	KIHIRA, K. et al., "Endoscopic Topical Therapy for the Treatment of Helicobacter Pylori Infection", Journal of Gastroenterology, 1996, pp 66-68, Vol. 31, Suppl IX	
	341	KIILERICH, S. et al., "Effect of Intravenous Infusion of Omeprazole and Rantidine on Twenty-Four Hour Intragastric pH in patients with Duodenal Ulcer", Digestion, 1995, pp 25-30, Vol. 56	
	342	KORPONAY-SZABO, I.R. et al., "High Acid Buffering Capacity of Protein Hydrolysate Infant Formulas", Journal of Pediatric Gastroenterology and Nutrition, August 2000, Vol. 31, Suppl 2, Abstract 956	
	343	KROMER, W. et al., "Differences in pH-Dependant Activation Rate of Substituted Benzimidazoles and Biological in vitro Correlates", Pharmacology, 1998, pp 57-70, Vol. 56	
	344	KROMER, W., "Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison Between Pantoprazole and Related Compounds", Digestion, 1995, pp443-454, Vol. 56, No. 6	
	345	LAGGNER, A.N. et al., "Prevention of Upper Gastrointestinal Bleeding in Long Term Ventilated Patients", American Journal of Medicine, 1989, pp 81-84, Vol. 86 Supp. 6A	
	346	LANDAHL S. et al., "Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers", Clinical Pharmacokinetics, 1992, pp 496-476, Vol. 23 No. 6	
	347	LARSON G.M. et al., "Gastric Response to Severe Head Injury", American Journal of Surgery, 1984, pp97-105, Vol. 147	
	348	LARSON, C., et al., "Bioavailability and Efficacy of Omeprazole Given Orally and by Nasogastric Tube", Digestive Diseases and Sciences, 1996, pp 475-479, Vol. 41, No. 3	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	38	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	349	LARSSON, H. et al., "Gastric Acid Antisecretory Effect of Two Different Dosage of Omeprazole During Prolonged Oral Treatment in the Gastric Fistula Dog", 1988, pp 1013-1019, Vol. 23, No. 8	
	350	LASKY, M., "A Prospective Study of Omeprazole Suspension to Prevent Clinically Significant Gastrointestinal Bleeding from Stress Ulcers in Mechanically Ventilated Trauma Patients", The Journal of Trauma: Injury Infection, and Critical Care", 1998, pp 527-533, Vol. 44, No. 3	
	351	LIN, M., et al., "Evaluation of Buffering Capacity and Acid Neutralizing pH Time Profile of Antacids", Journal of the Formosan Medical Association, 1998, pp 704-710, Vol. 97, No. 10	
	352	LIND, C. et al., "Inhibition of Basal and Betazole- and sham-feeding Induced Acid Secretion by Omeprazole in Man", Scandinavian Journal of Gastroenterology, 1986, pp 1004-1010, Vol. 21	
	353	LOCKHART, S.P. and BAXTER, G., "A Lansoprazole Suspension Formulation as an Alternative to Capsules for Oral Administration", World Congresses of Gastroenterology, 1998, P 226, Vol 59 Suppl 3. Abstract #ExhA2074	
	354	LONDONG, W. et al., "Dose-Response Study of Omeprazole on Meal-Stimulated Gastric Acid Secretion and Gastrin-Release", 1983, Gastroenterology, pp 1373-1378, Vol. 85, No. 6	
	355	MACONI, G. et al., "Prolonging Proton Pump Inhibitor-Based Anti-Helicobacter Pylori Treatment From One to Two Weeks in Duodenal Ulcer: Is it worthwhile?", Digest of Liver Disease, 2000, pp 275-280, Vol. 32	
	356	MARRONE, G.C. and SILEN, W., "Pathogenesis, Diagnosis and Treatment of Acute Gastric Mucosal Lesions", 1984, Clinics in Gastroenterology, pp 635-650, Vol.13 No. 2	
	357	MARTIN L.F. et al., "Continuous Intravenous Cimetidine Decreases Stress-Related Upper Gastrointestinal Hemorrhage Without Promoting Pneumonia", Critical Care Medicine, 1993, pp 19-39, Vol. 21 No. 1	
	358	MARTIN L.F. et al., "Stress Ulcers and Organ Failure in Intubated Patients in Surgical Intensive Care Units", Annals of Surgery, 1992, pp332-337, Vol.215 No. 4	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet	39	of	Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	359	MARTIN, A., et al., Physical Pharmacy Chemicals Principles in the Pharmaceutical Sciences, 1993, 4th Edition	
	360	MAXWELL, S.L. et al., "Control of Gastric pH in A Critical Care Unit: Physician Behavior and Pharmacologic Effectiveness", The American Review of Respiratory Disease, 1991, ppA482, Vol. 143, No. 4(Part 2)	
	361	McANDREWS, K.L. and Eastham J.H., "Omeprazole and Lansoprazole Suspensions for Nasogastric Administration", American Journal of Health-System Pharmacy, 1999, pp81, Vol. 56	
	362	McTAVISH, D. et al., "Omeprazole: An Updated Review of its Pharmacology and Therapeutic Use in Acid-Related Disorders", Drugs, 1991, pp138-170, Vol. 41 No. 1	
	363	Meiners, D. et al., "Evaluation of Various Techniques to Monitor Intragastric pH", Archives of Surgery, 1982, pp 288-291, Vol. 117	
	364	METZLER, M., "Advances in the Use of PPI's from Efficacy to Effectiveness", Presentation: Simplified Omeprazole Suspension", 1999	
	365	MOHIUDDIN, M.A. et al., "Effective Gastric Acid Suppression After Oral Administration of Enteric-Coated Omeprazole Granules", Digestive Diseases and Sciences, 1997, pp 715-719, Vol. 42, No. 4	
	366	NAKAGAWA, A. et al., "Lansoprazole:Phase I Study of Lansoprazole (AG-1749) Antiulcer Agent", Abstract in English; Text in Japanese, 1991, pp33-34	
	367	NAKAMURA, M. et al., "Effect of Combined Administration of lansoprazole and Sofalcone on Microvascular and Connective Tissue Regeneration after Ethanol-Induced Mucosal Damage", Journal of Clinical Gastroenterology, 1998, pp S170-177, Vol. 27 Supp. 1,	
	368	NAUNTON, M., et al., "Overuse of Proton Pump Inhibitors", Journal of Clinical Pharmacy and Therapeutics", 2000, pp 333-340, Vol. 25	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number		10/783,871	
		Filing Date		20-Feb-2004	
		First Named Inventor		Widder, et al.	
		Art Unit			
		Examiner Name			
Sheet	40	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	369	OH, M.S. and CARROLL H.J., "Electrolyte and Acid-Base Disorders", The Pharmacologic Approach to the Critically Ill Patient, 1994, pp957-968, 3rd Edition, Williams and Wilkins, Baltimore, U.S.A	
	370	OOSTERHUIS, B and JONKMAN, J.H.G., "Omeprazole: Pharmacology, Pharmacokinetics and Interactions", Digestion, 1989, pp 9-17, Vol. 44, Suppl 1	
	371	OSLER, P. et al., "Effect of Omeprazole on the Phosphate-Binding Capacity of Calcium Carbonate", Nephron, 1995, pp 89-90, Vol. 69	
	372	OSTRO, M.J. et al. "Control of Gastric pH with Cimetidine: Boluses Versus Primed Infusions", Gastroenterology, 1985, pp 532-537, Vol. 89 No. 3	
	373	PAUL, J., et al., "Pantoprazole Bicarbonate Suspension(PBS) Provides Oral Bioavailability Comparable to Tablet", Critical Care Medicine, 2001, 30th International Educational and Scientific Symposium, A563	
	374	PECKMAN, H.J., "Alternative Method for Administering Proton-Pump Inhibitors Through Nasogastric Tubes", American Journal of Health Systems Pharmacy, 1999, pp1020, Vol 56	
	375	PEURA, D.A. and JOHNSON, L.F. "Cimetidine for Prevention and Treatment of Gastroduodenal Mucosal Lesions in Patients in an Intensive Care Unit", Annals of Internal Medicine, 1985, pp173-177, Vol. 103 No. 2	
	376	PHILLIPS, J. "Stress-Related Mucosal Damage- Optimizing Drug Therapy", a presentation, 1997	
	377	PHILLIPS, J. and METZLER, M., "Simplified Omeprazole Solution for the Prophylaxis of Stress-Related Mucosal Damage in Critically Ill Patients", Critical Care Medicine, 1994, p A53, Vol. 22 No. 1	
	378	PHILLIPS, J.O. et al., "A Prospective Study of Simplified Omeprazole Suspension for the Prophylaxis of Stress-Related Mucosal Damage", Critical Care Medicine, 1996, pp 1793-1800, Vol. 24, No. 11	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet	41	of	47
		Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	379	PHILLIPS, D.H., "Interaction of Omeprazole with DNA in Rat Tissues", Mutagenesis, 1992, pp 277-283, Vol. 7, No. 4	
	380	PHILLIPS, "Simplified Omeprazole Solution-(S.O.S)- Pharmacokinetic/Pharmacodynamic Study in Patients at Risk for Stress Related Mucosal Damage(SRMD)" Project #5122, 1994	
	381	PHILLIPS, J., "Overview of Omeprazole Suspension-From Efficacy to Effectiveness Alternative Dosing of PPI's", 1998, a presentation	
	382	PHILLIPS, J., "Overview of Omeprazole Suspension-Problems with Administering Granules", 1999/2000, a presentation	
	383	PHILLIPS, J., "Simplified Omeprazole Suspension (SOS)", 1998, a presentation	
	384	PHILLIPS, J., "Stress-Related Mucosal Damage Optimizing Drug Therapy in the 1990's" presented by Phillips at University of Missouri Surgical Society Scientific Program, 1994	
	385	PHILLIPS, J., "Update on Acid-Related Disorders-Optimizing Pharmacotherapy for the 1990's", a presentation, 1996	
	386	PHILLIPS, J.O., et al., "The Stability of Simplified Omeprazole Suspension(SOS)", Critical Care Medicine, 1998, p A101, Vol.26, No. 1(Suppl), Abstract No. 221	
	387	PHILLIPS, J.O. et al., "A Multicenter, Prospective, Randomized Clinical Trail of Continuous Infusion I.V. Rantidine vs. Omeprazole Suspension in the Prophylaxis of Stress Ulcers", Cri Care Med, 1998, pp A101, Vol. 26, No. 1(Suppl) Abstract no. 222	
	388	PHILLIPS, J.O., "The Stablitiy of Simplified Lansoprazole Suspension(SLS)" Gastroenterology, Abstract G0382, Vol. 116, No. 4	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	42	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	389	PICKWORTH, K.K. et al., "Occurrence of Nasocomial Pneumonia in Mechanically Ventilated Trauma Patients: A Comparison of Sucralfate and ranitidine", Critical Care Medicine, 1993, pp1856-1862, Vol. 21 No. 12	
	390	PILBRANT, A. and CEDERBERG, C. et al., "Development of an Oral Formulation of Omeprazole." Scandinavian Journal of Gastroenterology, 1985, pp113-120, Vol. 20 Supp 108	
	391	PILBRANT, A. "Principles for Development of Antacids", Scandinavian Journal of Gastroenterology, 1982, pp 32-36, Vol. 75	
	392	PIPKIN, G.A. and MILLS, J.G., "Onset of Action of Antisecretory Drugs: Beneficial Effects of a Rapid Increase in Intragastric pH in Acid Reflux Disease", Scandinavian Journal of Gastroenterology., 1999, pp 3-8, Suppl. 230	
	393	PRICHARD, P.J. et al., "Omeprazole: A Study of its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage", Gastroenterology, 1985, pp 64-69, Vol. 88	
	394	PRIEBE, H. and SKILLMAN, J.J., "Methods of Prophylaxis in Stress Ulcer Disease", World Journal of Surgery, 1981, pp223-233, Vol. 5 No. 2	
	395	QUERCIA, R.A. et al., "Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid", American Journal of Health System Pharmacy, 1997, pp 1833-1836, Vol. 54, No. 16	
	396	REGARDH, C.G. et al., "The Pharmacokinetics of Omeprazole in Humans--a Study of Single Intravenous and Oral Doses", Therapeutic Drug Monitoring, 1990, pp163-172, Vol. 12, No. 2	
	397	REGARDH, et al., "Pharmacokinetics and metabolism of omeprazole in animals and man--an overview." Scandinavian Journal of Gastroenterology Suppl. 1985 pp79-94. Vol 108	
	398	RODRIGO, J.M. and PONCE, J., "Therapeutic Approach to Peptic Ulcer Relapse", Methods and Findings in Experimental and Clinical Pharmacology, 1989, pp 131-135, Vol. 11 Suppl. 1	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/783,871		
		Filing Date	20-Feb-2004		
		First Named Inventor	Widder, et al.		
		Art Unit			
		Examiner Name			
Sheet	43	of	47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	399	ROY, P.K. et al., "Zollinger-Ellison Syndrome-Clinical Presentation in 261 Patients", Medicine, 2000, pp 379-411, Vol. 79, No. 6	
	400	RYAN, P. et al., "Nosocomial Pneumonia During Stress Ulcer Prophylaxis with Cimetidine and Sucralfate", 1993, Archives of Surgery, pp1353-1357, Vol. 128	
	401	SAX, M.J. "Clinically Important Adverse Effects and Drug Interactions with H2-Receptor Antagonists: an Update", Pharmacotherapy, 1987, pp 110S-115S, Vol. 7 No. 6 pt. 2	
	402	SCHEPP, W., "Stress Ulcer Prophylaxis: Still a Valid Option in the 1990s?", Digestion, 1993, pp189-199, Vol. 54	
	403	SCHMASSMANN, A. et al., "Antacid Provides Better Restoration of Glandular Structures Within the Gastric Ulcer Scar than Omeprazole", Gut, 1994, pp 869-904, Vol. 35, No.7	
	404	SCHMASSMANN, A. et al., "Antacids in Experimental Gastric Ulcer Healing: Pharmacokinetics of Aluminum and Quality of Healing", European Journal of Gastroenterology & Hepatology, 1993, pp S111-S116, Vol. 5, Suppl. 3	
	405	SHUMAN, R.B. et al., "Prophylactic Therapy for Acute Ulcer Bleeding: a Reappraisal", Annals of Internal Medicine, 1987, pp562-567, Vol. 106	
	406	SCHUSTER, D.P. "Stress Ulcer Prophylaxis: in Whom? with What?", Critical Care Medicine, 1993, pp4-6, Vol. 21,	
	407	SECHET, A. et al., "Role of the Time of Administration of Calcium Carbonate in the Control of Hyperphosphemia in Patients on Maintenance Hemodialysis", Nephrologie, 1999, pp 209-212, Vol. 20, No. 4	
	408	SECHET, A. et al., "Inhibition of Gastric Secretion by Omeprazole and Efficacy of Calcium Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis", Nephrologie, 1999, pp 213-216, Vol.20, No. 4	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet	44	of	47
		Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	409	SHARMA V.K. et al., "The Effects on Intragastric Acidity of Per-Gastrostomy Administration of an Alkaline Suspension of Omeprazole", Alimentary Pharmacology & Therapeutics, 1999, pp 1091-1095, Vol. 13	
	410	SHARMA, V.K. et al., "Oral Pharmacokinetics of Omeprazole and Lansoprazole After Single and Repeated Doses as Intact Capsules or as Suspensions in Sodium Bicarbonate", Alimentary Pharmacology & Therapeutics", 2000, pp 887-892, Vol. 14, No. 7	
	411	SHARMA, V.K. et al., "The Pharmacodynamics of Lansoprazole Administered via Gastrostomy as Intact, Non-Encapsulated Granules", Alimentary Pharmacology & Therapeutics, 1998, pp 1171-1174, Vol. 12	
	412	SHARMA, V.K. et al., "Simplified Lansoprazole Suspension-A Liquid Formulation of Lansoprazole-Effectively Suppress Intragastric Acidity When Administered Through a Gastrostomy", American Journal of Gastroenterology, 1999, pp 1813-1817, Vol. 94, No. 7	
	413	SHARMA, V.K., "Comparison of 24-Hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole", American journal of Health System Pharmacy 1999, pp S180-S21, Vol. 56, Suppl 4	
	414	SHARMA, V.K. et al., "Effect on 24-Hour Intragastric Acidity of Simplified Omeprazole Solution(SOS) Administered via Gastrostomy", American Journal of Gastroenterology, 1997, p1625, Vol. 92, No. 9, Abstract #169	
	415	SHARMA, V.K., "Simplified Lansoprazole Suspension(SLS): A Proton Pump Inhibitor(PPI) in a Liquid Formulation that Works", American Journal of Gastroenterology, Sep. 1998, pp1647, Abstract #153	
	416	SIEPLER, J.K. et al., "Selecting Drug Therapy for Patients with Duodenal Ulcers", Clinical Pharmacy, 1990, pp 463-467, Vol. 9, No. 6	
	417	SIEPLER, J.K., "A Dosage Alternative for H-2 Receptor Antagonists, Continuous-Infusion", Clinical Therapeutics, 1986, pp24-33, Vol. 8 Suppl A	
	418	SIH, J.C. et al., "Studies on (H(+)-K+)-ATPase Inhibitors of Gastric Acid Secretion. Prodrugs of 2-[(2-Pyridinylmethyl)sulfinyl] benzimidazole Proton-pump Inhibitors", Journal of Medical Chemistry 1991, pp 1049-1062, Vol. 34, No. 3	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet 45	of 47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	419	SIMMS, H. et al., "Role of Gastric Colonization in the Development of Pneumonia in Critically Ill Trauma Patients: Results of a Prospective Randomized Trial", Journal of Trauma, 1991, pp 531-537, Vol. 31 No. 4	
	420	SKILLMAN, J.J. et al., "Respiratory Failure, Hypotension, Sepsis and Jaundice: a Clinical Syndrome Associated with Lethal Hemorrhage from Acute Stress Ulceration of the Stomach", American Journal of Surgery, 1969, pp 523-530, Vol. 117	
	421	SKILLMAN, J.J. et al., "The Gastric Mucosal Barrier: Clinical and Experimental Studies in Critically Ill and Norman Man, and in the Rabbit", Annals of Surgery, 1970, 564-584, Vol. 172 No. 4	
	422	SMYTHE, M.A. and ZAROWITZ, B.J., "Changing Perspectives of Stress Gastritis Prophylaxis", The Annals of Pharmacotherapy, 1994, pp1073-1085, Vol. 28	
	423	SPENCER, C.M. and FAULDS, D., "Esomeprazole", Drugs 2000, August 2000, pp 321-329, Vol. 60, No. 2	
	424	SPYCHAL, R.T. & WICKMAN, N.W.R., "Thrombocytopenia Associated with Rantidine", British Medical Journal, 1985, p 1687, Vol. 291	
	425	STRATFORD, M.R.L. et al., "Nicotinamide Pharmacokinetics in Humans: Effect of Gastric Acid Inhibition, Comparison of Rectal vs. Oral Administration and the Use of Saliva for Drug Monitoring", British Journal of Cancer, 1996, pp 16-21, Vol. 74, No. 1	
	426	TABATA, T. et al., "Stabilization of a New Antiulcer Drug(Lansoprazole) in the Solid Dosage Forms", Drug Development and Industrial Pharmacy, 1992, pp1437-1447, Vol. 18, No. 13	
	427	TAKEUCHI, K. et al., "Effects of Pantoprazole, a novel H+/K+-ATPase Inhibitor, on Duodenal Ulcerogenic and Healing Responses in Rats: a Comparative Study with Omeprazole and Lansoprazole", Journal of Gastroenterology and Hepatology, 1999, pp251-257, Vol. 14, No. 3	
	428	TANAKA, M. et al., "Differential Stereoselective Pharmacokinetics of Pantoprazole, a Proton Pump Inhibitor in Extensive and Poor Metabolizers of Pantoprazole- A Preliminary Study", Chirality, 1997, pp 17-21, Vol. 9	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet 46	of 47	Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	429	TANAKA, H. et al., "Pathogenesis of The Earliest Epithelial Cell Damage by Mepirazole and Cysteamine in the Rat Duodenum", Japanese Journal of Pharmacology, 1989, pp 509-519, Vol. 51, No. 4	
	430	THOMSON, A.B.R., "Are the Orally Administered Proton Pump Inhibitors Equivalent? A Comparison of Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole". Current Gastroenterology Reports, 2000, pp482-493, Vol. 2	
	431	TRYBA, M., "Risk of Acute Stress Bleeding and Nosocomial Pneumonia in Ventilated Intensive Care Patients, Sucralfate vs. Antacids", American Journal of Medicine, 1987, pp 117-124, Vol. 87 Suppl. 3B	
	432	TRYBA, M., "Stress Ulcer Prophylaxis-Quo Vadis?", Intensive Care Medicine, 1994, pp 311-313, Vol. 20	
	433	TYTGAT, G.N.J., "Drug Therapy of Reflux Oesophagitis: An Update," Scandinavian Journal of Gastroenterology, 1989, pp38-49, Vol. 24, Suppl 168	
	434	VIAL, T. et al., "Side Effects of Rantidine", Drug Safety, 1991, pp 94-117, Vol. 6 No. 2	
	435	VINCENT, J. et al., "Concurrent Administration of Omeprazole and Antacid Does Not Alter the Pharmacokinetics of Dofetilide in Healthy Subjects", Clinical Pharmacology & Therapeutics, 1996, p 182, Vol. 59, No. 2, Abstract P11-93	
	436	WADE, L.G., Organic Chemistry, 1987, pp349-350, Prentice-Hall, Inc., New Jersey, U.S.A	
	437	WALAN, A., "Pharmacological Agents for Peptic Ulcer Disease", Scandinavian Journal Gastroenterology, Suppl., 1984, p 1, Vol. 19, No. 98	
	438	WALLMARK, B. et al., "The Relationship Between Gastric Acid Secretion and Gastric H+/K+ - ATPase Activity", Journal of Biological Chemistry, 1985, 13681-13684, Vol. 260 No. 25	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/783,871
		Filing Date	20-Feb-2004
		First Named Inventor	Widder, et al.
		Art Unit	
		Examiner Name	
Sheet	47	of	47
		Attorney Docket Number	29635-714.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	439	WATANABE K. et al., "Pharmacokinetic Evaluation of Omeprazole Suspension Following Oral Administration in Rats:Effect of Neutralization of Gastric Acid", Acta Medica Okayama, 1996, pp 219-222, Vol. 50, No. 4	
	440	WILDER-SMITH, C.H. and MERKI, H.S., "Tolerance During Dosing with H2 Receptor Antagonists, An Overview", 1992, Scandinavian Journal of Gastroenterology, pp 14-19, Vol. 27 (Suppl 193)	
	441	WHIPPLE, J. et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements through the Nasogastric Tube", Critical Care Medicine, 1995, pp A69, Vol. 28, No.1(Suppl)	
	442	YAMAKAWA, T. et al., "Synthesis and Structure-Activity Relationships of Substituted 2-(2-Imidazolsulfinyl)methyl) anilines as a New Class of Gastric H+/K(+)-ATPase Inhibitors. II.", Chemical and Pharmaceutical Bulletin, 1992, pp675-682, Vol. 40, No. 3	
	443	YASUDA, S. et al., "Antacids Have No Influence of the Pharmacokinetics of Rabeprazole, A New Proton Pump Inhibitor, in Healthy Volunteers", International Journal of Clinical Pharmacology and Therapeutics, 1999, pp 249-253, Vol. 37, No. 5	
	444	ZINNER, M.J. et al., "The Prevention of Gastro-Intestinal Tract Bleeding in Patients in an Intensive Care Unit", Surgery, Gynecology and Obstetrics, pp 214-220, Vol. 153	
	445	"Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers", Chapter 37, pp 907-909	
	446	"Buffered and Isotonic Solutions", Physical Pharmacy, pp 169-189, Chap.8	
	447	"Pharmacotherapy Related Outcomes Group Researching Effective Stress Ulcer Strategies", Overview of Omeprazole Suspension 2000, a presentation	
	448	"Stress Ulcer Prophylaxis in the 21st Century", Overview of Omeprazole Suspension 2001, a presentation.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.